-
Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024
-
View Affiliations Hide AffiliationsSylvain Brissesbrisse pasteur.fr
-
View Collaborators
REMICOQ study group: Nathalie Brieu, Jenny Gallou, Audrey Homor, Morgane Choquet, Marie Kempf, Hélène Pailhoriès, Carine Dumollard, Dominique De Briel, Margaux Allain, Guilène Barnaud, Luce Landraud, Julien Bador, Gaëlle Cuzon, Benjamin Aubry, Jean Thomin, Ghislaine Descours, Ani Horikian, Anne-Lise Maucotel, Hélène Salord, Aubin Souche, Christelle Jost, Frederic Queuche, Agnès Ferroni, Chloé Plouzeau, Stéphane Bland, Hélène Petiprez, Marie Sarah Fangous, Florence Le Gall, Anne Vachee, Caroline PiauView Citation Hide Citation
Citation style for this article: . Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024. Euro Surveill. 2024;29(31):pii=2400459. https://doi.org/10.2807/1560-7917.ES.2024.29.31.2400459 Received: 15 Jul 2024; Accepted: 31 Jul 2024
- Previous Article
- Table of Contents
- Next Article
Abstract
As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.
![Loading full text...](/images/jp/spinner.gif)
Full text loading...
![](/images/commenting/icon_checkmark.png)